Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer’s disease
December 3, 2025
-
AlzeCure publishes its interim report for January – September 2025
November 11, 2025
-
Response letter to previous article published about Alzstatin’s unique mode of action against Alzheimer’s
October 14, 2025